These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 19705794

  • 1. [Comparative assessment of efficacy of the 3d generation cephalosporins, ceftriabol, and claforan, in patients with community-acquired pneumonia].
    Vakhrushev IaM, Starodubtseva OI.
    Klin Med (Mosk); 2009; 87(7):53-5. PubMed ID: 19705794
    [Abstract] [Full Text] [Related]

  • 2. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
    Starodubtseva OI, Vakhrushev IaM.
    Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
    [Abstract] [Full Text] [Related]

  • 3. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia].
    García-Contreras F, Del-Angel-García G, Ramírez Cuenca A, Malváez-Valdes M, Vega Yáñez A, Amato D.
    Rev Invest Clin; 2000; 52(4):418-26. PubMed ID: 11061104
    [Abstract] [Full Text] [Related]

  • 4. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC, MOTIV (MOxifloxacin Treatment IV) Study Group.
    Clin Infect Dis; 2008 May 15; 46(10):1499-509. PubMed ID: 18419482
    [Abstract] [Full Text] [Related]

  • 5. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy.
    Welte T, Petermann W, Schürmann D, Bauer TT, Reimnitz P, MOXIRAPID Study Group.
    Clin Infect Dis; 2005 Dec 15; 41(12):1697-705. PubMed ID: 16288390
    [Abstract] [Full Text] [Related]

  • 6. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia.
    Pertel PE, Bernardo P, Fogarty C, Matthews P, Northland R, Benvenuto M, Thorne GM, Luperchio SA, Arbeit RD, Alder J.
    Clin Infect Dis; 2008 Apr 15; 46(8):1142-51. PubMed ID: 18444848
    [Abstract] [Full Text] [Related]

  • 7. [Multicentre, randomized, prospective and comparative study of ceftriaxone, cefotaxime and cefuroxime in treating mild to moderate respiratory tract infection].
    Gao B, Hu J, Deng W.
    Zhonghua Jie He He Hu Xi Za Zhi; 1998 Sep 15; 21(9):528-31. PubMed ID: 11360502
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients.
    Parrish AG.
    S Afr Med J; 1998 Sep 15; 88(9):1046, 1048; author reply 1050-1. PubMed ID: 9798485
    [No Abstract] [Full Text] [Related]

  • 9. [Cefotaxime in sequential therapy of community acquired pneumonia].
    Wolska-Goszka L, Petlak A, Słomiński JM.
    Pol Merkur Lekarski; 1999 Sep 15; 7(39):99-101. PubMed ID: 10598482
    [Abstract] [Full Text] [Related]

  • 10. Severe community-acquired pneumonia in adults: current antimicrobial chemotherapy.
    Niven DJ, Laupland KB.
    Expert Rev Anti Infect Ther; 2009 Feb 15; 7(1):69-81. PubMed ID: 19622058
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Comparative analysis of the treatment of inpatients with community-acquired pneumonia and its different outcomes].
    Vizel' AA, Lysenko GV.
    Klin Med (Mosk); 2013 Feb 15; 91(3):41-4. PubMed ID: 23789451
    [Abstract] [Full Text] [Related]

  • 18. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
    Echols RM, Tillotson GS, Song JX, Tosiello RL.
    Clin Infect Dis; 2008 Dec 01; 47 Suppl 3():S166-75. PubMed ID: 18986284
    [Abstract] [Full Text] [Related]

  • 19. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
    Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R, 308 Study Group, 313 Study Group.
    Diagn Microbiol Infect Dis; 2008 Jul 01; 61(3):329-38. PubMed ID: 18508226
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.